From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Psychiatry>
  4. Summary and Comment

Possible Biologic Basis to SSRI-Related Suicidal Ideation

Initial genetic screening implicates markers within the glutamate signaling pathway.

Why do some patients taking antidepressants become vulnerable to suicidal ideation? To explore a possible biologic basis for this adverse effect, researchers used data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. The study population consisted of 1862 patients (age range, 18–75) who had received initial treatment with citalopram for depression and had genotype information available. Cases were 120 patients who self-reported treatment-emergent suicidal ideation; controls were the remaining 1742 patients. The investigators examined 68 candidate genes involved with glutamate, serotonin, dopamine, norepinephrine, and neurotrophin systems, as well as other pathways; within these, 768 single-nucleotide polymorphisms (SNPs) were chosen to sample common variation.

No between-group differences were found in clinical variables known to predict suicide. In participants with suicidal ideation, its onset developed relatively early in treatment (within 14 days in 21%; within 28 days in 92%). Two high-risk allele markers within the GR1K2 and GR1A3 genes, both of which are involved with encoding ionotropic glutamate receptors, were significantly associated with suicidal ideation, independent of citalopram dose.

Comment: Although the 68 candidate genes studied here seem pertinent, many other genes may also be influential, and many other genetic and nongenetic factors not yet identified may contribute to suicidal ideation (or suicide) in patients taking antidepressants. The identified alleles affect AMPA and kainite glutamate receptors known to change with antidepressant medications. Soon, perhaps, inexpensive, office-based genetic screening tools may permit clinicians to identify individual vulnerabilities and preemptively avoid specific adverse medication effects.

Joel Yager, MD

Published in Journal Watch Psychiatry January 7, 2008

Citation(s):

Laje G et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007 Oct; 164:1530.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Related Content

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2008. Massachusetts Medical Society. All rights reserved.